Elpiscience Biopharma, Astellas Pharma Collaborate For Novel Bi-specific Macrophage Engagers

From Give the media company name for www.nasdaq.com. Examples: “Reuters”, “CBS MarketWatch, “CNBC, “Wall Street Journal”, “Barchart”. Return only the company name after the headline.:

Elpiscience Biopharma, Ltd. and Astellas Pharma Inc. have signed a research collaboration and license agreement for novel bi-specific macrophage engagers, including ES019. Astellas can add up to two more programs to the collaboration. Elpiscience will receive up to $37 million, including an upfront payment and license option fees, as well as future milestones and royalty payments. Elpiscience will grant Astellas exclusive rights for further research, development, manufacturing, and commercialization for each program. The research funding from Astellas will advance the programs. If you want to read more health news, visit rttnews.com.



Read more: Elpiscience Biopharma, Astellas Pharma Collaborate For Novel Bi-specific Macrophage Engagers